STK018404|CAS 314757-93-2|DC Chemicals

Cas No.:	314757-93-2
Chemical Name:	4-{2-2,4,6-Trioxotetrahydro-5(2H)-pyrimidinylidenehydrazino}benzoic acid
Synonyms:	4-[2-(2,4,6-trioxotetrahydro-5(2H)-pyrimidinylidene)hydrazino]benzoic acid;4-{2-[2,4,6-Trioxotetrahydro-5(2H)-pyrimidinylidene]hydrazino}benzoic acid;ARONIS019830;HMS1608P02;4-[(6-hydroxy-2,4-dioxo-1H-pyrimidin-5-yl)diazenyl]benzoic acid;STK018404;STL344118;STL559670;ST036587;4-[2-(2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene)hydrazino]benzoic acid;4-[(2E)-2-(2,6-dihydroxy-4-oxopyrimidin-5(4H)-
SMILES:	OC1=C(C(NC(N1)=O)=O)/N=N/C1C=CC(C(=O)O)=CC=1
Formula:	C₁₁H₈N₄O₅
M.Wt:	276.205021858215
Purity:	98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

MSDS

Cat. No.	Product name	Field of application
DC74245	STK018404	STK018404 is a small molecule inhibitor of RNA-binding protein human antigen R (HuR), decreases the binding of HuR to its target RNA motif.
DC70499	HuR inhibitor KH-3	HuR inhibitor KH-3 is a small molecule, selective inhibitior of HuR function with Ki of 0.83 and 0.72 uM in FP and AlphaLISA assays, respectively.KH-3 potently inhibits breast cancer cell growth in vitro and in vivo.KH-3 inhibits breast cancer cell invasion in vitro as well as delays initiation of lung colonies and improves mouse survival in an experimental metastasis model in vivo.KH-3 suppresses breast cancer cell invasion by disrupting HuR-FOXQ1 mRNA interaction.Inhibition of HuR with KH-3 yielded a significant reduced in the progression of pathological cardiac hypertrophy in a transverse aortic constriction model.